CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. (CASI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
casi · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CASI Pharmaceuticals, Inc. (CASI) measures how much investors pay for each dollar of the company's trailing earnings. CASI's current PE ratio of N/A is calculated by dividing its stock price of $0.15 by its TTM earnings per share of -$3.08.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CASI Pharmaceuticals, Inc.You CASI | $2M | N/A | — | -$3.08 |
 Allarity Therapeutics, Inc. ALLR | $26M | N/A | — | -$0.78 |
 Cingulate Inc. CING | $27M | N/A | — | -$4.13 |
 Clearside Biomedical, Inc. CLSD | $2M | N/A | — | -$6.98 |
 Curis, Inc. CRIS | $6M | N/A | — | -$0.06 |
 Entero Therapeutics, Inc. ENTO | $14M | N/A | — | -$4.05 |
 Kairos Pharma, Ltd. KAPA | $10M | N/A | — | -$0.30 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-2.56 | — | |
2023-12-31 FY2023 | — | $-2.02 | — | |
2022-12-31 FY2022 | — | $-3.01 | — | |
2021-12-31 FY2021 | — | $-2.69 | — | |
2020-12-31 FY2020 | — | $-4.37 | — | |
2019-12-31 FY2019 | — | $-4.73 | — | |
2018-12-31 FY2018 | — | $-3.24 | — | |
2017-12-31 FY2017 | — | $-1.75 | — | |
2016-12-31 FY2016 | — | $-1.69 | — | |
2015-12-31 FY2015 | — | $-2.22 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CASI Pharmaceuticals, Inc. (CASI) measures how much investors pay for each dollar of the company's trailing earnings. CASI's current PE ratio of N/A is calculated by dividing its stock price of $0.15 by its TTM earnings per share of -$3.08.
Frequently asked questions
CASI pe ratio · 6 questionsCASI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.15 and TTM EPS of -$3.08. Data sourced from Financial Modeling Prep via CASI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CASI Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09